Symbio Completes Patient Enrollment For Bendamustine Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Symbio Pharmaceuticals has commenced a Phase II trial in Japan for Treaksym (bendamustine, SyBL-501) for patients with relapsed and intractable multiple myeloma.